NeuroPace (NPCE) Cash from Financing Activities (2020 - 2026)
NeuroPace (NPCE) posted quarterly Cash from Financing Activities of -$166000.0 for Q1 2026, down 100.79% year-over-year from $21.1 million in Q1 2025, and down 126.14% quarter-over-quarter from $635000.0 in Q4 2025.
NeuroPace (NPCE) Cash from Financing Activities (2020 - 2026) Analysis & Trends
NeuroPace's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$166000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 100.79% year-over-year to -$166000.0; the TTM figure through Mar 2026 stood at -$1.7 million (down 106.6% YoY), while the FY2025 annual figure was $19.6 million, up 352.97% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$166000.0, down from $635000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $21.1 million in Q1 2025, with the low at -$1.9 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is $72000.0 (2024), against an average of $1.9 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 25600.0% in 2023, then soared 29216.67% in 2025.
- NeuroPace's Cash from Financing Activities stood at -$138000.0 in 2022, then jumped by 6052.17% to $8.2 million in 2023, then tumbled by 89.68% to $848000.0 in 2024, then decreased by 25.12% to $635000.0 in 2025, then plunged by 126.14% to -$166000.0 in 2026.
- Business Quant data shows NPCE's Cash from Financing Activities at -$166000.0 in Q1 2026, $635000.0 in Q4 2025, and -$235000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | NeuroPace | 479.51 Mn | 427.81 Mn | 18.91 Mn | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | -166,000.00 |
| Mar 31, 2026 | -166,000.00 |
| Dec 31, 2025 | 635,000.00 |
| Dec 31, 2025 | 635,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Jun 30, 2025 | -1.91 Mn |
| Jun 30, 2025 | -1.91 Mn |
| Mar 31, 2025 | 21.11 Mn |
| Mar 31, 2025 | 21.11 Mn |
| Dec 31, 2024 | 848,000.00 |
| Dec 31, 2024 | 848,000.00 |
| Sep 30, 2024 | 2.90 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 509,000.00 |
| Jun 30, 2024 | 509,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Mar 31, 2024 | 72,000.00 |